Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan; Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
J Pharmacol Sci. 2021 Nov;147(3):245-250. doi: 10.1016/j.jphs.2021.07.006. Epub 2021 Aug 5.
Sodium/glucose cotransporter 2 (SGLT2) is a renal low-affinity high-capacity sodium/glucose cotransporter expressed in the apical membrane of the early segment of proximal tubules. SGLT2 reabsorbs filtered glucose in the kidney, and its inhibitors represent a new class of oral medications used for type 2 diabetes mellitus, which act by increasing glucose and sodium excretion in urine, thereby reducing blood glucose levels. However, clinical trials showed marked improvement of renal outcomes, even in nondiabetic kidney diseases, although the underlying mechanism of this renoprotective effect is unclear. We showed that long-term excretion of salt by the kidneys, which predisposes to osmotic diuresis and water loss, induces a systemic body response for water conservation. The energy-intensive nature of water conservation leads to a reprioritization of systemic body energy metabolism. According to current data, use of SGLT2 inhibitors may result in similar reprioritization of energy metabolism to prevent dehydration. In this review article, we discuss the beneficial effects of SGLT2 inhibition from the perspective of energy metabolism and water conservation.
钠/葡萄糖协同转运蛋白 2(SGLT2)是一种低亲和力、高容量的肾脏钠/葡萄糖协同转运蛋白,表达于近端肾小管早期段的顶膜上。SGLT2 在肾脏中重吸收滤过的葡萄糖,其抑制剂是一种新型的口服药物,用于 2 型糖尿病,通过增加尿中葡萄糖和钠的排泄来降低血糖水平。然而,临床试验显示,即使在非糖尿病肾脏疾病中,SGLT2 抑制剂也能显著改善肾脏结局,但其潜在的肾保护作用机制尚不清楚。我们表明,肾脏长期排盐会导致渗透性利尿和水分流失,从而引发全身的水合作用反应。水合作用的能量密集特性导致全身能量代谢的重新优先化。根据现有数据,使用 SGLT2 抑制剂可能会导致类似的能量代谢重新优先化,以防止脱水。在这篇综述文章中,我们从能量代谢和水合作用的角度讨论 SGLT2 抑制的有益作用。